Board of Directors

Claire is a trained molecular and cellular biologist with extensive experience leading preclinical and clinical drug development programs. Claire marries the breadth of her broad technological reach, with prime experience in all stages of investments (Seed, A, B, C, IPO, PIPE, SPAC) which she acquired in established corporate venture funds. With this totality, she has proven to be a catalyst for organizations developing transformative technologies, where she is known to build bespoke deal financing structures and business models to generate progress in the community.

Claire has a PhD from the Institute of Genetics, Molecular and Cellular Biology of Strasbourg-Illkirch France, and a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School (Cambridge MA). She has 14 years of experience in drug development acquired at Forenap Pharma, Wyeth Pharmaceuticals, and Pfizer Inc. She was an investor at Samsung Venture America (SVA), Johnson & Johnson Development Corporation (JJDC), and most recently was an Entrepreneur in Residence at the National Institutes of Health (Bethesda, MD).